Platelet response to aspirin in Chinese stroke patients is independent of genetic polymorphisms of COX-1 C50T and COX-2 G765C

Journal of Atherosclerosis and Thrombosis

Volumn 20, Issue 1, 2013, Pages 65-72

  Yi, Xingyang ^a   Zhou, Qiang ^a   Lin, Jing ^a   Chi, Lifen ^a   Han, Zhao ^b  

^a THE THIRD AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Aspirin resistance; Cyclooxygenase; Platelet function tests; Polymorphism; Stroke

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CREATININE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPING TECHNIQUE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PROSPECTIVE STUDY; THROMBOCYTE AGGREGATION;

AGED; ASPIRIN; BASE SEQUENCE; BLOOD PLATELETS; CHINA; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; STROKE; THROMBOXANE B2;

EID: 84873834347     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.14092     Document Type: Article

References (39)

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial Infarction: ISIS-2. Lancet, 1988; 2: 349-360
2. Antithrombotic Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy - II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ, 1994; 308: 159-168
3. Antithrombotic Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy - III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ, 1994; 308: 235-246
4. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002; 324: 71-86
5. McKee SA, Sane DC, Deliargyris EN: Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost, 2002; 88: 711-715
6. Howard PA: Aspirin resistance. Ann Pharmacother, 2002; 36: 1620-1624
7. Bhatt DL, Topol EJ: Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov, 2003; 2: 15-28
8. Catella F, Lawson JA, Fitzgerald DJ, FitzGerald GA: Analysis of multiple thromboxane metabolites in plasma and urine. Adv Prostaglandin Thromboxane Leukot Res, 1987; 17B: 611-614
9. McConnell JP, Cheryk LA, Durocher A, Bruno A, Bang NU, Fleck JD, Williams LS, Biller J, Meschia JF: Urinary 11-dehydrothromboxane B2 and coagulation activation markers measured within 24 hours of human acute ischemic stroke. Neurosci Lett, 2001; 313: 88-92
10. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A: Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol, 2005; 95: 973-975
11. Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, Vered Z, Krakover R, Kaluski E, Kornberg A: Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004; 147: 293-300
12. Frelinger AL, III, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD: Residual arachidonic acidinduced platelet activation via an adenosine diphosphatedependent but cyclooxygenase-1- and cyclooxygenase-2- independent pathway: a 700-patient study of aspirin resistance. Circulation, 2006; 113: 2888-2896
13. Goodman T, Sharma P, Ferro A: The genetics of aspirin resistance. Int J Clin Pract, 2007; 61: 826-834
14. Kunicki TJ, Williams SA, Nugent DJ, Harrison P, Segal HC, Syed A, Rothwell PM: Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb Haemost, 2009; 101: 123-133
15. Chakroun T, Addad F, Yacoub S, Abderrezak F, Gerotziafas GT, Abdelkafi S, Hassine M, Gamra H, Hatmi M, Elalamy I: The cyclooxygenase-1 C50T polymorphism is not associated with aspirin responsiveness status in stable coronary artery disease in Tunisian patients. Genet Test Mol Biomarkers, 2011; 15: 513-516
16. Goodman T, Ferro A, Sharma P: Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol, 2008; 66: 222-232
17. Lee PY, Chen WH, Ng W, Cheng X, Kwok JY, Tse HF, et al: Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med, 2005; 118: 723-727
18. Halushka MK, Walker LP, Halushka PV: Genetic variation in cyclooxygenase1: effects on response to aspirin. Clin Pharmacol Ther, 2003; 73: 122-130
19. Colaizzo D, Fofi L, Tiscia G, Guglielmi R, Cocomazzi N, Prencipe M, Margaglione M, Toni D: The COX-2 G/C -765 polymorphism may modulate the occurrence of cerebrovascular ischemia. Blood Coagul Fibrinolysis, 2006; 17: 93-96
20. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, Mezzetti A: A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA, 2004; 291:2221-2228
21. Frelinger AL, III, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD: Residual arachidonic acidinduced platelet activation via an adenosine diphosphatedependent but cyclooxygenase-1- and cyclooxygenase-2- independent pathway: a 700-patient study of aspirin resistance. Circulation, 2006; 113: 2888-2896
22. Meen O, Brosstad F, Khiabani H, Gjertsen E, Lauritsen ME, Pedersen TM, Bjornsen S, Schjelderup NM, Ameln W, Ng EC, Wettergreen M, Siddique SP, Erikssen G.: No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. Scand J Clin Lab Invest, 2008; 68: 185-191
23. Maree AO, Curtin RJ, Chubb A, Dolan C, Cox D, O'Brien J, Crean P, Shields DC, Fitzgerald DJ: Cyclooxygenase- 1 haplotype modulates platelet response to aspirin. J Thromb Haemost, 2005; 3: 2340-2345
24. Nicholson NS, Panzer-Knodle SG, Haas NF, Taite BB, Szalony JA, Page JD, Feigen LP, Lansky DM, Salyers AK: Assessment of platelet function assays. Am Heart J, 1998; 135: S170-S178
25. Rodgers RP, Levin J: Bleeding time: a guide to its diagnostic and clinical utility. Arch Pathol Lab Med, 1990; 114: 1187-1188
26. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK: Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost, 2006; 4: 312-319
27. Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Coller BS: Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation, 1999; 99: 620-625
28. Cattaneo M: Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol, 2004; 24: 1980-1987
29. Harrison P: Progress in the assessment of platelet function. Br J Haematol, 2000; 111: 733-744
30. Michelson AD, Frelinger AL, III, Furman MI: Current options in platelet function testing. Am J Cardiol, 2006; 98: S4, 10
31. Han SW, Kim SH, Lee JY, et al: A new subtype classification of ischemic stroke based on treatment and etiologic mechanism. Eur Neurol, 2007; 57: 96-102
32. Patrono C: Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost, 2003; 1: 1710-1713
33. Bhatt DL, Topol EJ: Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov, 2003; 2: 15-28
34. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol, 2001; 88: 230-235
35. Patrono C, Rocca B: Aspirin: Promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol, 2008; 28: 25-32
36. Sanderson S, Emery J, Baglin T, et al: Narrative review: Aspirin resistance and its clinical implications. Ann Intern Med, 2005; 142: 370-380
37. Eikelboom JW, Hankey GJ: Aspirin resistance: A new independent predictor of vascular events? J Am Coll Cardiol, 2003; 41: 966-968
38. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG: A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J, 2007; 28: 1702-1708
39. Rink C, Khanna S: Significance of brain tissue oxygenation and the arachidonic acid cascade in stroke. Antioxid Redox Signal, 2011; 14: 1889-1903